Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
27 mars 2024 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
20 mars 2024 02h00 HE
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative...
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
12 mars 2024 12h00 HE
|
Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
07 févr. 2024 08h00 HE
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic...
Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain
18 janv. 2024 08h00 HE
|
KIZOO Technology Capital GmbH
SAN FRANCISCO and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Reservoir Neuroscience announced today the completion of a $4M financing round to support the development of new therapies for age-related...
Neuronic Welcomes Light Therapy Experts to its Scientific Advisory Board
31 août 2023 10h00 HE
|
Neuronic Devices Operations GmbH
EGG HARBOR, N.J, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Neuronic, a pioneering company in the field of photobiomodulation (PBM) technology, also known as light therapy, is proud to announce the...
APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II
23 août 2023 17h21 HE
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...
Neuronic and Santa Clara University partner to develop next-gen neurotech for photobiomodulation guided by real-time brain activity
11 mai 2023 12h00 HE
|
Neuronic Devices Operations GmbH
Integrating photobiomodulation with neurofeedback will revolutionize treatment of brain disorders SANTA CLARA, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Neuronic, a multi-national company focused...
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
25 janv. 2023 04h00 HE
|
AKAMPION
- Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated...
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
29 nov. 2022 04h00 HE
|
AKAMPION
- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing...